TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Alpha diversity of cervical microbiota
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in Chlamydia in cervical carcinoma group
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Increase in Proteobacteria in hrHPV infected cervical discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: abnormal half filling time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: abnormal third filling time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: total filling time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Sedation success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to achieve sedation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Length of stay in DCU
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: adherence rate with glaucoma medications
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of lumbar epidural venous puncture
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 1-year major adverse event (MAE) free survival
Endpoint domain: Mortality/survival
Primary endpoint: Serum alpha-amylase levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Morphine consumption in the first 24 postoperative hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: knee injury incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Total risks across all time points
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduced discomfort
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduced procedure problems
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Proportion of days without heartburn
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative improvement rates of heartburn
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with complete heartburn resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: adipose tissue concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma lipid oxidation lag times
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma protein carbonyl formation at lysine residues
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 12-month incidence of endometrial hyperplasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: incidence of grade 3 or higher hypertension
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in VMS frequency and severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in nighttime awakenings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in sleep duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fecal amounts of Lactobacilli and Bifidobacteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: decreasing aggressive and violent behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Residual pain at 1 year
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ACE activity reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: mean zinc serum level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: choroidal neovascular membrane (CNV) detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: visual loss caused by CNV
Endpoint domain: Adverse events/effects
Primary endpoint: Satisfaction with the CHW program
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Satisfaction with the public-sector health system
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of patients completing four cycles of TPF‐E
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients who experienced severe complications
Endpoint domain: Adverse events/effects
Primary endpoint: Mortality rate during the study
Endpoint domain: Mortality/survival
Primary endpoint: Impairment in psychomotor function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Increased response errors during impulsivity tasks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: EuroQol scores visual analog scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Bioequivalence of Matrifen and Durogesic DTrans
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficient utilization of fentanyl
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lower intra- and inter-subject variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: motor and sensory parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: re-restenosis rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: acute gain by IVUS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: lumen diameter late loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Vaccine efficacy against any-severity RVGE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of CIAKI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Fistula formation rates
Endpoint domain: Adverse events/effects
Primary endpoint: Flap necrosis rates
Endpoint domain: Adverse events/effects
Primary endpoint: Cosmetic appearance
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Peak aerobic capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ramsay Sedation Scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Critical-Care Pain Observation Tool score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of postoperative air leakage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intra-operative air leakage intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time until chest drain removal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Worst VAS for pain at 3 months follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of analgesic tablets taken at the end of treatment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: basal acid output
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Physical fatigue at 18 weeks
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: General fatigue at 36 weeks
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: mean change scores for correctness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: rhinorrhea facial pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: intensity of headache
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: inferior turbinate hypertrophy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thyroid volume (TV) increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in serum FT3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in serum FT4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CIGTS VF score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glaucoma Hemifield Test (GHT) results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of INR measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical correlation leading to different therapeutic decisions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient preference for blood sampling method
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Attendance at psychiatry appointment
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Detection of additional lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Cytolytic/oncolytic activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NK cell percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of drug-related problems
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Continuous chronic pain at 1 year after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: formation of functional filtering blebs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Early diastolic function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Heart rate variability changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean scores for vascular opacification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: loco-regional control rate
Endpoint domain: Mortality/survival
Primary endpoint: cumulative rectal and bladder complication rate
Endpoint domain: Adverse events/effects
Primary endpoint: Cognitive decline or death
Endpoint domain: Mortality/survival
Primary endpoint: clinical manifestations of neuropathy grades ≥2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Degree of pigmentation decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: major adverse cardiac event
Endpoint domain: Mortality/survival
Primary endpoint: angina pectoris reoccurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Partial and complete response rate (PR + CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Median time to disease progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Survival rates (1, 2, 3, and 5 years)
Endpoint domain: Mortality/survival
Primary endpoint: BMI Z-scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Metabolic risk factors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Days of parenteral nutrition (PN)
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: CTX-II levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Median inhibitory concentration (IC50) of parasites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal LTB4 synthesis inhibition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LDL to HDL ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Hemostatic success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Time to controlled bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Time to complete hemostasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Improvement or stabilization of disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Contact with general practitioner at 1 month post-release
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Contact with general practitioner at 3 months post-release
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Contact with mental health services at 6 months post-release
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Prevalence of CKD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urine protein levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to virologic failure
Endpoint domain: Mortality/survival
Primary endpoint: Time in which the pH was ≤ 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Reduction in death or institutional care
Endpoint domain: Mortality/survival
Primary endpoint: Lesion length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Scaled edge-length ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Caregiver stress and distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: body size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: metabolic health variables
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Increase in ankle range of motion (ROM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: perceived susceptibility to breast cancer
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean decrease in plasma HIV-1 RNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hypnotic use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal voluntary inspiratory mouth pressure (MIP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Maximal voluntary expiratory mouth pressure (MEP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Oswestry disability index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of disease progression
Endpoint domain: Mortality/survival
Primary endpoint: Percent change in CD4 cells during therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of decline in HIV RNA in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: New systemic corticosteroid prescriptions per patient
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Total systemic corticosteroid burden
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Agreement between first diagnosis and second opinion pathology review
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GCF PGE2 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Suppression of inflammatory pathways in AD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: increase in serum iron
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Anginal complaints improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maternal and perinatal mortality rates
Endpoint domain: Mortality/survival
Primary endpoint: Serum PTH level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean increase of CoQ10 plasma concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the curve values (AUC(inf))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: success rates for complete miscarriage
Endpoint domain: Mortality/survival
Primary endpoint: Number of relapses
Endpoint domain: Mortality/survival
Primary endpoint: Image quality of CCA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: freedom from recurrent AF/atrial tachycardia
Endpoint domain: Mortality/survival
Primary endpoint: Disability improvement (Oswestry score)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Trunk muscle endurance improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective response to therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: air trapping index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: KE strength and endurance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chair-rising time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hospitalizations due to malaria episodes
Endpoint domain: Adverse events/effects
Primary endpoint: blood transfusions due to malaria episodes
Endpoint domain: Adverse events/effects
Primary endpoint: time to clinical AIDS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: adaptive resilience score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Patch test positivity rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Discussion of cancer-related risks with physician
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participation in health screening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: balance and functional ability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SF‐36 scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: 30 day-hospital mortality
Endpoint domain: Mortality/survival
Primary endpoint: requirement of inotropic agents
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: cardiac index at 2 hours after bypass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean score on the QUOOC
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Accuracy at matching optic nerve photographs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Differences in TPD scores between LEHR and IQ·SPECT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of nerve lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Reduction in apo B levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Median time to morphine rescue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Morphine consumption over 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peripheral FD in DR eyes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global nonperfusion area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Control of lymphoproliferation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Circulating T follicular helper cell frequencies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: increase individualized and appropriate colorectal cancer screening
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Efficacy of PP-3M
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerability of PP-3M
Endpoint domain: Adverse events/effects
Primary endpoint: Safety of PP-3M
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of femoral head osteonecrosis
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of re-dislocation
Endpoint domain: Adverse events/effects
Primary endpoint: Virus isolation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Episcleral Venous Pressure (EVP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Post-dural puncture headache (PPDPH)
Endpoint domain: Adverse events/effects
Primary endpoint: percentage of weight loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of neutrophils in sputum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Nitrogen oxides (nitrate and nitrite) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Improvements in stroke care
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence to pharmacological venous thromboembolism prophylaxis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients receiving 100% of scheduled doses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient refusal as a reason for omitted doses
Endpoint domain: Adverse events/effects
Primary endpoint: Withdrawals due to asthma
Endpoint domain: Adverse events/effects
Primary endpoint: Local-progression-free survival (LPFS)
Endpoint domain: Mortality/survival